Company intelligence / Profile preview

Bioretina Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Bioretina Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative gene therapies for ophthalmic diseases, particularly retinal disorders. The company leverages its proprietary Adeno-Associated Virus (AAV) platform to create long-lasting treatments that aim to reduce the burden of frequent intravitreal injections for patients with conditions like wet age-related macular degeneration. Its lead candidate, BRN-01, is designed to provide sustained expression of anti-VEGF proteins within the eye. Bioretina is headquartered in China and has established research and manufacturing facilities to support its growing pipeline of ocular therapies.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAAV gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Bioretina Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioretina Biotechnology.

Explore the full profile